Deals
Funds managed by Northleaf Capital Partners (Northleaf) have acquired a 90 per cent stake in Douglas Terminals from Hartree Partners (UK) Limited (Hartree) and Ghent Transport & Storage NV (GTS).Douglas Terminals is a 557,000-cubic metre liquid bulk storage terminal based in the Port of Ghent, Belgium. The facility consists of 17 high-quality tanks currently used for the storage of jet fuel, gasoil, diesel and biodiesel. Hartree and GTS started commercial operations at the terminal in 2017. GTS will retain a 10 per cent stake and continue to operate the terminal under a management services agreement. As part of the transaction,
Varagon Capital Partners, a direct lender to middle market companies, is to form a new strategic partnership with Aflac Global Investments (Aflac) and is extending its existing strategic partnership with American International Group (AIG).Upon closing of the new partnership, Aflac will make a new multi-year investment commitment of up to USD3.0 billion to Varagon to invest in middle market loans. Aflac will also acquire a significant non-controlling minority interest in Varagon, creating a mutually-beneficial partnership and demonstrating a commitment to a long-term relationship.
Aflac will acquire the interests in Varagon currently held by certain former and current partners and
Edinburgh-based biotech startup MiAlgae has received an investment of GBP1 million to focus on the commercialisation of its revolutionary microalgae product, targeting the rapidly growing global aquaculture and pet food industries.The biotech business uses co-products from the whisky distillation process to produce microalgae, which is high in omega 3 and other nutrients. The algae can be used to sustainably feed fish and create animal food. MiAlgae estimates that one tonne of its algae saves up to 30 tonnes of wild fish.
MiAlgae will use the investment to double the size of its business premises, commission a demonstrator plant in East
Novo Seeds’ portfolio company, NorthSea Therapeutics a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, has successfully closed a USD40 million (EUR36 million) Series B financing round.The proceeds of this fundraising will be used by NST to drive the development of its pipeline of SEFA (Structural Engineered Fatty Acids) programs. The Company will develop two additional SEFAs within its clinical pipeline in addition to completing the Phase 2b with its lead candidate Icosabutate.
In addition to Novo Seeds, existing investors, Forbion, New Science Ventures (NSV)
British MedTech business, OrganOx Ltd, has secured a GBP4.6 million investment from BGF, the UK and Ireland’s most active investor in growing businesses.The investment will fund commercial expansion of its first product, the metra, in the US, building on commercial traction in Europe, Canada and Australia.
OrganOx metra is the world’s first fully automated system for keeping a human donor liver functioning for up to 24 hours outside the body. The invention breaks with 40 years of traditional organ preservation in ice, doubling the time that donor organs can be preserved. The device mimics the environment of the human
Private equity firm Entrepreneurial Equity Partners’ (e2p) portfolio company, Daniele International, has completed a merger with Creminelli Fine Meats (Creminelli). Financial terms of the transaction have not been disclosed.Creminelli is a producer and distributor of premium charcuterie and protein snacks, known for exceptional quality and recognised with 11 national food awards. Creminelli’s product lines include charcuterie snack trays, deli trays, artisan salami, artisan deli, and salami minis. Creminelli’s approach of using ultra-premium ingredients and small-batch production was inherited from generations of Master Artisan Cristiano Creminelli’s family and has been maintained through the company’s rapid growth. Creminelli’s clean-label inputs and use of humanely
Iptor, a specialist in distribution and supply chain management, planning and logistics software and services, has been acquired by Bregal Unternehmerkapital alongside investment from current CEO Jayne Archbold and Chief Marketing and Product Officer Christopher Catterfeld. Bregal Unternehmerkapital is a growth-focused investment firm whose principal focus is to invest behind sound business models and strong leadership teams.
Iptor has been transformed over the past three years under the leadership of Archbold and Catterfeld. The re-branding and re-positioning of the business from IBS to Iptor has delivered exceptional progress, with the product portfolio having been transformed through the successful launch of the
TAS Environmental Services (TAS), a portfolio company of Blue Point Capital Partners’ Fund IV has acquired Specialized Waste Systems (SWS) (www.specializedwaste.com), a provider of hazardous and non-hazardous waste management, transportation and washout services.
Ironwood Capital’s portfolio company, precision manufacturer NSA Industries (NSA), has acquired Vitex Extrusions (Vitex), a Franklin, New Hampshire-based manufacturer of metal extrusions. “When we originally invested in NSA in late 2017, the plan was to continue company expansion and diversification through organic growth and strategic acquisitions,” says Alex Levental, Ironwood Capital managing director. “NSA did not have extrusion capability. With the Vitex acquisition, NSA adds to the breadth of its capabilities and expands the company’s sales into the transportation, consumer durable goods, building products, and electrical products end markets.”
“NSA is an existing customer of Vitex, so this acquisition is a
ESTEVE is to acquire all the shares of the German pharmaceutical company RIEMSER from private investment house Ardian.Headquartered in Berlin, RIEMSER has a diversified portfolio of products with the three main therapeutic areas being: oncology, neurology and niche therapies. RIEMSER operates a pharmaceutical manufacturing plant in Germany and has direct geographical presence in four of Europe’s five major countries: Germany, United Kingdom, France, and Spain. Over 80 per cent of sales come from the hospital channel, providing specialty treatments and a wide range of pharmaceuticals in therapeutic niche areas.
ESTEVE’s purchase of RIEMSER will accelerate its transformation into a specialty pharma company
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
